FDA Says “No Evidence” Second Course Of Paxlovid Is Effective In Rebound Cases

Bloomberg (5/4, Langreth) reports “there is ‘no evidence’ that a second course of Pfizer Inc.’s Paxlovid will help” patients with COVID-19 “whose symptoms return after an initial course of the antiviral, a U.S. Food and Drug Administration official said a...